Challenges for imaging angiogenesis.

Angiogenesis, the sprouting of new capillaries from existing blood vessels, and vasculogenesis, the de novo generation of blood vessels, are the two primary methods of vascular expansion by which nutrient supply to tissues is adjusted to match physiological demand. Accordingly, vasculogenesis is an integral and essential component of embryonic development, and angiogenesis accompanies organ growth and regeneration [1]. Angiogenesis also occurs during wound repair, in spontaneous growth of collateral vessels in response to ischaemia, in the ovaries and uterus during the female reproductive cycle, in retinopathy and in cancer. The angiogenic process is a complex multistep phenomenon involving many growth factors and interactions between a number of cell types [2]. Angiogenesis is invoked by expression of pro-angiogenic growth factors in cells of the target tissue and by suppression of anti-angiogenic factors. Expression of angiogenic growth factors can be induced as a response to hypoxic stress, by hormonal stimulation, but can also result from activation of oncogenes. Normal vessels activated by vascular endothelial growth factor (VEGF) respond within minutes by dilation and increased permeability to macromolecular serum proteins. Extravasation of plasma proteins leads to deposition of a provisional extracellular matrix (ECM), which facilitates endothelial cell migration. Prior to endothelial proliferation and migration, activated vessels show local shedding of pericytes and smooth muscle cells. These perivascular cells are essential for maintaining vascular integrity but also further suppress endothelial cell proliferation. Proliferation, migration and elongation of endothelial capillaries require degradation of the ECM, and endothelial cells thus activated release a number of proteolytic enzymes, including collagenase. Tumours may benefit from the ECM remodelling and growth factors released during the early stages of angiogenesis, even in the absence of increased perfusion [3]. This process leads to the generation of a functional but immature endothelial plexus. The final stages of angiogenesis include stabilization, remodelling and maturation of the new vessels by recruitment of pericytes and smooth muscle cells.

[1]  D M Shames,et al.  Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. , 1996, Radiology.

[2]  A. Kaider,et al.  Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease‐free survival , 1997, International journal of cancer.

[3]  D. Chaplin,et al.  Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. , 1999, Anticancer research.

[4]  P. Vermeulen,et al.  Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. , 1999, The cancer journal from Scientific American.

[5]  P. Carmeliet,et al.  Molecular mechanisms of blood vessel growth. , 2001, Cardiovascular research.

[6]  R. Davis,et al.  In vivo detection and imaging of phosphatidylserine expression during programmed cell death. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Dario Neri,et al.  Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform , 1997, Nature Biotechnology.

[8]  T. Henry Science, medicine, and the future: Therapeutic angiogenesis , 1999 .

[9]  R. Henriksson,et al.  Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Norton,et al.  Immunophenotype of intraductal carcinoma. , 1996, Archives of pathology & laboratory medicine.

[11]  P. Rao,et al.  Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. , 1998, British Journal of Cancer.

[12]  M. Nguyen,et al.  Regression of Metastatic Breast Cancer in a Patient Treated with the Anti-Angiogenic Drug Tnp-470 , 1999, Tumori.

[13]  H. Augustin,et al.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.

[14]  David A. Cheresh,et al.  Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging , 1998, Nature Medicine.

[15]  A. Alavi,et al.  Role of radionuclide imaging in trials of antiangiogenic therapy. , 2000, Academic radiology.

[16]  M. Dewhirst,et al.  Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. , 2000, Journal of the National Cancer Institute.

[17]  K W Ferrara,et al.  Evaluation of tumor angiogenesis with US: imaging, Doppler, and contrast agents. , 2000, Academic radiology.

[18]  J. Isner,et al.  Stimulation of peripheral angiogenesis by vascular endothelial growth factor (VEGF). , 1998, VASA. Zeitschrift fur Gefasskrankheiten.

[19]  J. Folkman New perspectives in clinical oncology from angiogenesis research. , 1996, European journal of cancer.

[20]  Michal Neeman,et al.  In Vivo Prediction of Vascular Susceptibility to Vascular Endothelial Growth Factor Withdrawal Magnetic Resonance Imaging of C6 Rat Glioma in Nude Mice , 1999 .

[21]  N. van Bruggen,et al.  Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. , 1998, Cancer investigation.

[22]  R. Gilles,et al.  Ductal carcinoma in situ: MR imaging-histopathologic correlation. , 1995, Radiology.

[23]  G. Sledge,et al.  Redefining the target: chemotherapeutics as antiangiogenics. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  T. Haas,et al.  Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: implications for angiogenesis. , 1999, Trends in cardiovascular medicine.

[25]  R Weissleder,et al.  Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. , 2000, European journal of cancer.

[26]  K. Miles,et al.  Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. , 1999, European journal of radiology.

[27]  C. Verschraegen,et al.  Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. , 1998, The New England journal of medicine.

[28]  Chien-Nan Lee,et al.  Vascularity index as a novel parameter for the in vivo assessment of angiogenesis in patients with cervical carcinoma , 1999, Cancer.

[29]  E. Fishman,et al.  Application of CT in the investigation of angiogenesis in oncology. , 2000, Academic radiology.

[30]  N. Weidner,et al.  Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow , 1998, The Journal of pathology.

[31]  A R Padhani,et al.  In vivo monitoring of tumor angiogenesis with MR imaging. , 2000, Academic radiology.

[32]  R. Kerbel,et al.  Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. , 1995, Anti-cancer drugs.